|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBMS3 |
Gene summary for RBMS3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBMS3 | Gene ID | 27303 |
| Gene name | RNA binding motif single stranded interacting protein 3 | |
| Gene Alias | RBMS3 | |
| Cytomap | 3p24.1 | |
| Gene Type | protein-coding | GO ID | GO:0002347 | UniProtAcc | Q6XE24 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27303 | RBMS3 | P8T-E | Human | Esophagus | ESCC | 1.41e-10 | 4.14e-01 | 0.0889 |
| 27303 | RBMS3 | P10T-E | Human | Esophagus | ESCC | 2.31e-14 | 2.82e-01 | 0.116 |
| 27303 | RBMS3 | P11T-E | Human | Esophagus | ESCC | 1.92e-03 | 2.10e-01 | 0.1426 |
| 27303 | RBMS3 | P16T-E | Human | Esophagus | ESCC | 6.16e-33 | 6.49e-01 | 0.1153 |
| 27303 | RBMS3 | P23T-E | Human | Esophagus | ESCC | 1.48e-07 | 1.51e-01 | 0.108 |
| 27303 | RBMS3 | P24T-E | Human | Esophagus | ESCC | 1.91e-02 | 1.20e-01 | 0.1287 |
| 27303 | RBMS3 | P26T-E | Human | Esophagus | ESCC | 8.82e-25 | 4.49e-01 | 0.1276 |
| 27303 | RBMS3 | P27T-E | Human | Esophagus | ESCC | 2.27e-02 | 1.39e-01 | 0.1055 |
| 27303 | RBMS3 | P32T-E | Human | Esophagus | ESCC | 3.46e-05 | 1.79e-01 | 0.1666 |
| 27303 | RBMS3 | P36T-E | Human | Esophagus | ESCC | 1.40e-07 | 3.25e-01 | 0.1187 |
| 27303 | RBMS3 | P37T-E | Human | Esophagus | ESCC | 4.77e-03 | 1.01e-01 | 0.1371 |
| 27303 | RBMS3 | P39T-E | Human | Esophagus | ESCC | 8.10e-07 | 1.39e-01 | 0.0894 |
| 27303 | RBMS3 | P42T-E | Human | Esophagus | ESCC | 3.18e-05 | 1.89e-01 | 0.1175 |
| 27303 | RBMS3 | P44T-E | Human | Esophagus | ESCC | 1.75e-02 | 1.60e-01 | 0.1096 |
| 27303 | RBMS3 | P47T-E | Human | Esophagus | ESCC | 1.75e-03 | 1.05e-01 | 0.1067 |
| 27303 | RBMS3 | P49T-E | Human | Esophagus | ESCC | 1.02e-03 | 3.63e-01 | 0.1768 |
| 27303 | RBMS3 | P54T-E | Human | Esophagus | ESCC | 3.39e-10 | 2.11e-01 | 0.0975 |
| 27303 | RBMS3 | P57T-E | Human | Esophagus | ESCC | 1.86e-02 | 1.36e-01 | 0.0926 |
| 27303 | RBMS3 | P61T-E | Human | Esophagus | ESCC | 2.00e-04 | 9.70e-02 | 0.099 |
| 27303 | RBMS3 | P74T-E | Human | Esophagus | ESCC | 1.93e-03 | 1.67e-01 | 0.1479 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605522 | Lung | AAH | Wnt signaling pathway | 28/613 | 444/18723 | 7.63e-04 | 2.63e-02 | 28 |
| GO:019873822 | Lung | AAH | cell-cell signaling by wnt | 28/613 | 446/18723 | 8.18e-04 | 2.75e-02 | 28 |
| GO:003011122 | Lung | MIAC | regulation of Wnt signaling pathway | 41/967 | 328/18723 | 1.51e-07 | 3.69e-05 | 41 |
| GO:001605531 | Lung | MIAC | Wnt signaling pathway | 50/967 | 444/18723 | 1.88e-07 | 4.02e-05 | 50 |
| GO:019873831 | Lung | MIAC | cell-cell signaling by wnt | 50/967 | 446/18723 | 2.16e-07 | 4.11e-05 | 50 |
| GO:006082822 | Lung | MIAC | regulation of canonical Wnt signaling pathway | 28/967 | 253/18723 | 1.23e-04 | 5.10e-03 | 28 |
| GO:006007022 | Lung | MIAC | canonical Wnt signaling pathway | 31/967 | 303/18723 | 2.31e-04 | 7.86e-03 | 31 |
| GO:00301782 | Lung | MIAC | negative regulation of Wnt signaling pathway | 19/967 | 170/18723 | 1.28e-03 | 2.38e-02 | 19 |
| GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
| GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
| GO:003011110 | Oral cavity | OSCC | regulation of Wnt signaling pathway | 165/7305 | 328/18723 | 1.87e-05 | 1.80e-04 | 165 |
| GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
| GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
| GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
| GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
| GO:003011123 | Oral cavity | EOLP | regulation of Wnt signaling pathway | 67/2218 | 328/18723 | 5.11e-06 | 1.04e-04 | 67 |
| GO:006082823 | Oral cavity | EOLP | regulation of canonical Wnt signaling pathway | 54/2218 | 253/18723 | 1.11e-05 | 1.95e-04 | 54 |
| GO:006007023 | Oral cavity | EOLP | canonical Wnt signaling pathway | 61/2218 | 303/18723 | 2.11e-05 | 3.28e-04 | 61 |
| GO:001605532 | Oral cavity | NEOLP | Wnt signaling pathway | 93/2005 | 444/18723 | 1.35e-10 | 1.34e-08 | 93 |
| GO:019873832 | Oral cavity | NEOLP | cell-cell signaling by wnt | 93/2005 | 446/18723 | 1.73e-10 | 1.66e-08 | 93 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBMS3 | SNV | Missense_Mutation | novel | c.254G>T | p.Gly85Val | p.G85V | Q6XE24 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| RBMS3 | SNV | Missense_Mutation | novel | c.812N>C | p.Ser271Thr | p.S271T | Q6XE24 | protein_coding | tolerated(0.06) | benign(0.109) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBMS3 | SNV | Missense_Mutation | novel | c.520N>T | p.Asp174Tyr | p.D174Y | Q6XE24 | protein_coding | deleterious(0.03) | probably_damaging(0.984) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBMS3 | SNV | Missense_Mutation | c.724N>T | p.Pro242Ser | p.P242S | Q6XE24 | protein_coding | tolerated(0.29) | benign(0.005) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RBMS3 | SNV | Missense_Mutation | c.611N>T | p.Tyr204Phe | p.Y204F | Q6XE24 | protein_coding | tolerated(0.71) | benign(0.012) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RBMS3 | SNV | Missense_Mutation | novel | c.76N>A | p.Gln26Lys | p.Q26K | Q6XE24 | protein_coding | tolerated_low_confidence(0.4) | benign(0.01) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RBMS3 | insertion | Frame_Shift_Ins | novel | c.678_679insG | p.Gln227AlafsTer30 | p.Q227Afs*30 | Q6XE24 | protein_coding | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| RBMS3 | SNV | Missense_Mutation | c.447N>G | p.Ile149Met | p.I149M | Q6XE24 | protein_coding | tolerated(0.05) | benign(0.043) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RBMS3 | SNV | Missense_Mutation | c.449N>A | p.Ser150Tyr | p.S150Y | Q6XE24 | protein_coding | tolerated(0.13) | benign(0.443) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RBMS3 | SNV | Missense_Mutation | c.425T>A | p.Leu142Gln | p.L142Q | Q6XE24 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3693-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 27303 | RBMS3 | NA | Bisphosphonates |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |